What’s Next for Codexis, Inc. (CDXS) After Making 52-Week High?

May 22, 2018 - By Marguerite Chambers

Codexis, Inc. (NASDAQ:CDXS) Logo

Investors sentiment decreased to 2.17 in 2017 Q4. Its down 0.03, from 2.2 in 2017Q3. It dived, as 3 investors sold Codexis, Inc. shares while 15 reduced holdings. 12 funds opened positions while 27 raised stakes. 28.02 million shares or 9.42% more from 25.60 million shares in 2017Q3 were reported.
Bancorporation Of Montreal Can accumulated 1,324 shares. Voya Inv Mgmt has invested 0% of its portfolio in Codexis, Inc. (NASDAQ:CDXS). Amer International invested 0% in Codexis, Inc. (NASDAQ:CDXS). Perkins Cap reported 30,000 shares or 0.24% of all its holdings. Geode Capital Limited Liability Co reported 0% of its portfolio in Codexis, Inc. (NASDAQ:CDXS). Laurion Capital Management Limited Partnership stated it has 0% in Codexis, Inc. (NASDAQ:CDXS). Moreover, Parametric Associate Ltd Limited Liability Company has 0% invested in Codexis, Inc. (NASDAQ:CDXS) for 14,925 shares. Goldman Sachs Gp Inc stated it has 0% in Codexis, Inc. (NASDAQ:CDXS). Deutsche State Bank Ag owns 107,089 shares. Moreover, State Street has 0% invested in Codexis, Inc. (NASDAQ:CDXS) for 645,477 shares. Balyasny Asset Management Limited Liability Corporation holds 0% or 11,845 shares. Vanguard Gru has 0% invested in Codexis, Inc. (NASDAQ:CDXS). Morgan Stanley owns 91,201 shares for 0% of their portfolio. State Board Of Administration Of Florida Retirement Systems reported 44,892 shares. Retail Bank Of Mellon stated it has 161,350 shares or 0% of all its holdings.

Since March 21, 2018, it had 0 buys, and 7 sales for $1.73 million activity. WOLF DENNIS P had sold 41,666 shares worth $464,384. Lalonde James sold 20,000 shares worth $259,930. Shares for $283,945 were sold by Aldridge Michael D. on Tuesday, May 15. Smith David V sold 6,000 shares worth $62,213. NICOLS JOHN J sold $259,828 worth of stock. The insider BARUCH THOMAS R sold $276,318.

The stock of Codexis, Inc. (NASDAQ:CDXS) hit a new 52-week high and has $14.72 target or 4.00 % above today’s $14.15 share price. The 6 months bullish chart indicates low risk for the $753.35M company. The 1-year high was reported on May, 22 by Barchart.com. If the $14.72 price target is reached, the company will be worth $30.13M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.35% or $0.05 during the last trading session, reaching $14.15. About 155,670 shares traded. Codexis, Inc. (NASDAQ:CDXS) has risen 125.77% since May 22, 2017 and is uptrending. It has outperformed by 114.22% the S&P500.

Analysts await Codexis, Inc. (NASDAQ:CDXS) to report earnings on August, 8. They expect $-0.03 EPS, up 76.92 % or $0.10 from last year’s $-0.13 per share. After $-0.10 actual EPS reported by Codexis, Inc. for the previous quarter, Wall Street now forecasts -70.00 % EPS growth.

Codexis, Inc. (NASDAQ:CDXS) Ratings Coverage

Among 2 analysts covering Codexis (NASDAQ:CDXS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Codexis had 2 analyst reports since March 12, 2018 according to SRatingsIntel. Stephens initiated the stock with “Buy” rating in Wednesday, May 16 report. The rating was maintained by H.C. Wainwright on Monday, March 12 with “Buy”.

More notable recent Codexis, Inc. (NASDAQ:CDXS) news were published by: Seekingalpha.com which released: “Codexis’ (CDXS) CEO John Nicols on Q1 2018 Results – Earnings Call Transcript” on May 11, 2018, also Fool.com with their article: “3 High-Growth Stocks That Are Just Getting Started” published on May 12, 2018, Globenewswire.com published: “Codexis Reports First Quarter 2018 Financial Results” on May 10, 2018. More interesting news about Codexis, Inc. (NASDAQ:CDXS) were released by: Globenewswire.com and their article: “Codexis to Hold First Quarter 2018 Conference Call on May 10” published on May 03, 2018 as well as Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: May 16, 2018.

Codexis, Inc. discovers, develops, and sells protein catalysts. The company has market cap of $753.35 million. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable clients to perform chemistry screening. It currently has negative earnings. The firm also provides protein catalyst screening and protein engineering services.

Codexis, Inc. (NASDAQ:CDXS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.